First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.

Publication

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.

Journal Paper/Review - May 11, 2023

Eichhorst Barbara, Niemann Carsten Utoft, Kater Arnon P, Fürstenau Moritz, von Tresckow Julia, Zhang Can, Robrecht Sandra, Gregor Michael, Juliusson Gunnar, Thornton Patrick, Staber Philipp B, Tadmor Tamar, Lindstrom Vesa, da Cunha-Bang Caspar, Schneider Christof, Poulsen Christian Bjørn, Illmer Thomas, Schöttker Björn, Noesslinger Thomas, Janssens Ann, Christiansen Ilse, Baumann Michael, Frederiksen Henrik, Klift Marjolein van der, Jäger Ulrich, Leys Maria B L, Hoogendoorn Mels, Lotfi Kourosh, Hebart Holger, Gaska Tobias, Koene Harry, Enggaard Lisbeth, Goede Jereon, Regelink Josien, Widmer Anouk Andrea, Simon Florian, De Silva Nisha, Fink Anna Maria, Bahlo Jasmin, Fischer Kirsten, Wendtner Clemens-Martin, Kreuzer Karl A, Ritgen Matthias, Brüggemann Monika, Tausch Eugen, Levin Mark-David, van Oers Marinus, Geisler Christian, Stilgenbauer Stephan, Hallek Michael, GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland

Citation

Eichhorst B, Niemann C, Kater A, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber P, Tadmor T, Lindstrom V, da Cunha-Bang C, Schneider C, Poulsen C, Illmer T, Schöttker B, Noesslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, Klift M, Jäger U, Leys M, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink J, Widmer A, Simon F, De Silva N, Fink A, Bahlo J, Fischer K, Wendtner C, Kreuzer K, Ritgen M, Brüggemann M, Tausch E, Levin M, van Oers M, Geisler C, Stilgenbauer S, Hallek M, GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. N Engl J Med 2023; 388:1739-1754.

Type

Journal Paper/Review (English)

Journal

N Engl J Med 2023; 388

Publication Date

May 11, 2023

Issn Electronic

1533-4406

Pages

1739-1754

Brief description/objective

Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking.